Astrocytoma, IDH-mutant, grade 3
Clinical trials for Astrocytoma, IDH-mutant, grade 3 explained in plain language.
Never miss a new study
Get alerted when new Astrocytoma, IDH-mutant, grade 3 trials appear
Sign up with your email to follow new studies for Astrocytoma, IDH-mutant, grade 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New brain tumor drug combo enters final testing phase
Disease control Recruiting nowThis Phase III trial is testing whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of brain tumor (IDH-mutated grade 3 astrocytoma). About 408 participants will receive either vorasidenib or a pla…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for brain tumor patients: targeted drug shows promise in phase 3 trial
Disease control Recruiting nowThis study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for brain cancer patients: experimental combo enters trials
Disease control Recruiting nowThis study tests a new drug (Debio 0123) combined with standard chemotherapy (temozolomide) and sometimes radiation in adults with glioblastoma, an aggressive brain cancer. The goal is to find the safest dose and see if the combination helps people live longer. About 116 particip…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase 1/2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Promising drug combo targets Hard-to-Treat brain cancers
Disease control Recruiting nowThis study tests two drugs—retifanlimab (an immunotherapy) and DFMO (a growth blocker)—alone or together in 33 adults with progressive high-grade glioma, an aggressive brain cancer. The goal is to find the safest, most effective dose and see if the combination boosts the immune s…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC